135 related articles for article (PubMed ID: 37209540)
21. Long-term Survival and Cost-effectiveness Associated With Axicabtagene Ciloleucel vs Chemotherapy for Treatment of B-Cell Lymphoma.
Whittington MD; McQueen RB; Ollendorf DA; Kumar VM; Chapman RH; Tice JA; Pearson SD; Campbell JD
JAMA Netw Open; 2019 Feb; 2(2):e190035. PubMed ID: 30794298
[TBL] [Abstract][Full Text] [Related]
22. Axicabtagene ciloleucel compared to standard of care in Swedish patients with large B-cell lymphoma: a cost-effectiveness analysis of the ZUMA-7 trial.
Loftager ASL; Danø A; Eklund O; Vadgama S; Hedlof Kanje V; Munk E
J Med Econ; 2023; 26(1):1303-1317. PubMed ID: 37725082
[TBL] [Abstract][Full Text] [Related]
23. Cost-Effectiveness of Axicabtagene Ciloleucel for Adult Patients With Relapsed or Refractory Follicular Lymphoma in the United States.
Oluwole OO; Ray MD; Rosettie KL; Ball G; Jacob J; Bilir SP; Patel AR; Jacobson CA
Value Health; 2024 Apr; ():. PubMed ID: 38641058
[TBL] [Abstract][Full Text] [Related]
24. Cost-Effectiveness of Brexucabtagene Autoleucel versus Best Supportive Care for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma following Treatment with a Bruton's Tyrosine Kinase Inhibitor in Canada.
Ball G; Lemieux C; Cameron D; Seftel MD
Curr Oncol; 2022 Mar; 29(3):2021-2045. PubMed ID: 35323364
[TBL] [Abstract][Full Text] [Related]
25. Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Multiply Relapsed or Refractory Adult Large B-Cell Lymphoma.
Lin JK; Muffly LS; Spinner MA; Barnes JI; Owens DK; Goldhaber-Fiebert JD
J Clin Oncol; 2019 Aug; 37(24):2105-2119. PubMed ID: 31157579
[TBL] [Abstract][Full Text] [Related]
26. Cost-Effectiveness Analysis of Axicabtagene Ciloleucel vs. Tisagenlecleucel for the Management of Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Spain.
Bastos-Oreiro M; de Las Heras A; Presa M; Casado MA; Pardo C; Martín-Escudero V; Sureda A
Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158805
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of blinatumomab versus salvage chemotherapy in relapsed or refractory Philadelphia-chromosome-negative B-precursor acute lymphoblastic leukemia from a US payer perspective.
Delea TE; Amdahl J; Boyko D; Hagiwara M; Zimmerman ZF; Franklin JL; Cong Z; Hechmati G; Stein A
J Med Econ; 2017 Sep; 20(9):911-922. PubMed ID: 28631497
[TBL] [Abstract][Full Text] [Related]
28. An updated cost-effectiveness analysis of axicabtagene ciloleucel in second-line large B-cell lymphoma patients in the United States.
Oluwole OO; Patel AR; Vadgama S; Smith NJ; Blissett R; Feng C; Dickinson M; Johnston PB; Perales MA
J Med Econ; 2024; 27(1):77-83. PubMed ID: 38053517
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of brentuximab vedotin for relapsed or refractory systemic anaplastic large-cell lymphoma in China.
Liu J; Zheng L; Chuang LH
J Med Econ; 2022; 25(1):99-107. PubMed ID: 34927526
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of second-line lisocabtagene maraleucel in relapsed or refractory diffuse large B-cell lymphoma.
Choe JH; Yu T; Abramson JS; Abou-El-Enein M
Blood Adv; 2024 Jan; 8(2):484-496. PubMed ID: 38153350
[TBL] [Abstract][Full Text] [Related]
31. Cost-Effectiveness of Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel and Tisagenlecleucel in the Third-Line or Later Treatment Setting for Relapsed or Refractory Large B-cell Lymphoma in the United States.
Parker C; Liu FF; Deger KA; Franco-Villalobos C; Proskorovsky I; Keating SJ; Sorensen S
Adv Ther; 2023 May; 40(5):2355-2374. PubMed ID: 36947328
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of relmacabtagene autoleucel, an anti-CD19 chimeric antigen receptor T cell, in relapsed/refractory B-cell non-Hodgkin's lymphoma: 2-year results of a phase 1 trial.
Ying Z; Xie Y; Zheng W; Liu W; Lin N; Tu M; Wang X; Ping L; Deng L; Zhang C; Wu M; Feng F; Du T; Tang Y; Su F; Guo Z; Li J; Song Y; Zhu J
Bone Marrow Transplant; 2023 Mar; 58(3):288-294. PubMed ID: 36477110
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphoma.
Potnis KC; Di M; Isufi I; Gowda L; Seropian SE; Foss FM; Forman HP; Huntington SF
Blood Adv; 2023 Mar; 7(5):801-810. PubMed ID: 36342852
[TBL] [Abstract][Full Text] [Related]
34. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial.
Kamdar M; Solomon SR; Arnason J; Johnston PB; Glass B; Bachanova V; Ibrahimi S; Mielke S; Mutsaers P; Hernandez-Ilizaliturri F; Izutsu K; Morschhauser F; Lunning M; Maloney DG; Crotta A; Montheard S; Previtali A; Stepan L; Ogasawara K; Mack T; Abramson JS;
Lancet; 2022 Jun; 399(10343):2294-2308. PubMed ID: 35717989
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness of idecabtagene vicleucel compared with conventional care in triple-class exposed relapsed/refractory multiple myeloma patients in Canada and France.
Karampampa K; Zhang W; Venkatachalam M; Cotte FE; Dhanda D
J Med Econ; 2023; 26(1):243-253. PubMed ID: 36705644
[TBL] [Abstract][Full Text] [Related]
36. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness analysis of KTE-X19 CAR T therapy versus real-world standard of care in patients with relapsed/refractory mantle cell lymphoma post BTKi in England.
Petersohn S; Salles G; Wang M; Wu J; Wade SW; Simons CL; Bennison C; Siddiqi R; Peng W; Kloos I; Castaigne G; Hess G
J Med Econ; 2022; 25(1):730-740. PubMed ID: 35611697
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness for KTE-X19 CAR T therapy for adult patients with relapsed/refractory mantle cell lymphoma in the United States.
Simons CL; Malone D; Wang M; Maglinte GA; Inocencio T; Wade SW; Bennison C; Shah B
J Med Econ; 2021; 24(1):421-431. PubMed ID: 33634729
[TBL] [Abstract][Full Text] [Related]
39. Prophylaxis for
Huang X; Huang X; Lin S; Luo S; Dong L; Lin D; Huang Y; Xie C; Nian D; Xu X; Weng X
BMJ Open; 2023 Mar; 13(3):e068943. PubMed ID: 36972963
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness of polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma.
Patel KK; Isufi I; Kothari S; Foss F; Huntington S
Leuk Lymphoma; 2020 Dec; 61(14):3387-3394. PubMed ID: 32835553
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]